Champions Story

CSBR -- USA Stock

USD 11.64 0.24 2.11%

Macroaxis Story

Champions Oncology Debt to Equity Ratio is relatively stable at the moment as compared to the past year. Champions Oncology reported last year Debt to Equity Ratio of 2.90. As of 09/14/2020, Free Cash Flow per Share is likely to grow to 0.06, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (1.1 M). Champions Oncology is scheduled to announce its earnings today. The upcoming quarterly report is expected on the 21st of September 2020. Many investors are getting excited about healthcare space, let's analyze if Champions Oncology fundamentals are strong enough to attract traders. We will evaluate why recent Champions Oncology price moves suggest a bounce in October. We currently estimate Champions Oncology as undervalued. The real value is approaching 8.60 per share.

Published over three months ago

View all stories for Champions Oncology | View All Stories

How Champions Oncology (NASDAQ:CSBR) weak basic indicators helped with the latest fall?

We provide trade advice to complement the prevailing expert consensus on Champions Oncology. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. The company dividends can provide a clue to the current value of the stock. This firm is not expected to issue dividends this year as it is trying to preserve or re-invest any of the funds available for distribution to stakeholders.

Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Champions Oncology income statement, its balance sheet, and the statement of cash flows. Potential Champions Oncology investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Champions Oncology investors may use each financial statement separately, they are all related. The changes in Champions Oncology's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Champions Oncology's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages. The goal of Champions Oncology fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Champions Oncology performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Champions Oncology shares is the value that is considered the true value of the share. If the intrinsic value Champions is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Champions Oncology. Please read more on our fundamental analysis page.

Are Champions Oncology Earnings Expected to grow?

The future earnings power of Champions Oncology involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Champions Oncology factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Champions Oncology stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Champions expected earnings.

How Champions utilizes its cash?

To perform a cash flow analysis of Champions Oncology, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Champions Oncology is receiving and how much cash it distributes out in a given period. The Champions Oncology cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Champions Oncology Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. Champions Oncology reported last year Net Cash Flow from Operations of 3.34 Million

Champions Oncology Gross Profit

Champions Oncology Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Champions Oncology previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Champions Oncology Gross Profit growth over the last 10 years. Please check Gross Profit in more details.

Going after Champions Financials

Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of Champions Oncology is not uncomon. Institutional investors typically avoid acquiring a high percentage of Champions Oncology stocks because performing such an act may violate securities laws. They are usually not investing their own money, but rather making investments on behalf of their clients. Let's take a look at how the ownership of Champions is distributed among investors.

Ownership Allocation

Champions Oncology retains a total of 12.73 Million outstanding shares. Over half of Champions Oncology outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in Champions Oncology. Please watch out for any change in the institutional holdings of Champions Oncology as this could mean something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Retail Investors

27.87%

Insiders

20.78%

Institutions

51.35%

	Retail Investors	27.87
	Insiders	20.78
	Institutions	51.35

	2017	2018	2019	2020 (projected)
Revenues USD	20.24 M	27.07 M	32.12 M	34.66 M
Revenues	20.24 M	27.07 M	32.12 M	34.66 M

Revenues USD Revenues

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Champions Oncology has an asset utilization ratio of 556.0 percent. This connotes that the company is making $5.56 for each dollar of assets. An increasing asset utilization means that Champions Oncology is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets

11.6 M

Assets Non Current

7.8 M

Current Assets	11.63 Million	58.43
Assets Non Current	7.83 Million	39.33
Goodwill	445,215	2.24

Are Champions Oncology technical ratios showing a relapse?

The mean deviation is down to 2.75 as of today. Champions Oncology exhibits very low volatility with skewness of -0.45 and kurtosis of 0.38. However, we advise investors to further study Champions Oncology technical indicators to make sure all market info is available and is reliable.

Our Conclusion on Champions Oncology

While few other entities in the biotechnology industry are either recovering or due for a correction, Champions Oncology may not be performing as strong as the other in terms of long-term growth potentials. The inconsistency in the assessment between current Champions valuation and our trade advice on Champions Oncology is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Champions Oncology.

About Contributor

Ellen Johnson is a Member of Macroaxs Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management. View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Champions Oncology. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2021 Macroaxis LLC